These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29416923)

  • 1. Bispecific tumor-penetrating protein anti-EGFR-iRGD efficiently enhances the infiltration of lymphocytes in gastric cancer.
    Zhu A; Sha H; Su S; Chen F; Wei J; Meng F; Yang Y; Du J; Shao J; Ji F; Zhou C; Zou Z; Qian X; Liu B
    Am J Cancer Res; 2018; 8(1):91-105. PubMed ID: 29416923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy.
    Sha H; Zou Z; Xin K; Bian X; Cai X; Lu W; Chen J; Chen G; Huang L; Blair AM; Cao P; Liu B
    J Control Release; 2015 Feb; 200():188-200. PubMed ID: 25553823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tumor-penetrating recombinant protein anti-EGFR-iRGD enhance efficacy of paclitaxel in 3D multicellular spheroids and gastric cancer in vivo.
    Sha H; Li R; Bian X; Liu Q; Xie C; Xin X; Kong W; Qian X; Jiang X; Hu W; Liu B
    Eur J Pharm Sci; 2015 Sep; 77():60-72. PubMed ID: 25998561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An iRGD peptide fused superantigen mutant induced tumor-targeting and T lymphocyte infiltrating in cancer immunotherapy.
    Song Y; Xu M; Li Y; Li Y; Gu W; Halimu G; Fu X; Zhang H; Zhang C
    Int J Pharm; 2020 Aug; 586():119498. PubMed ID: 32505575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer.
    Ding N; Zou Z; Sha H; Su S; Qian H; Meng F; Chen F; Du S; Zhou S; Chen H; Zhang L; Yang J; Wei J; Liu B
    Nat Commun; 2019 Mar; 10(1):1336. PubMed ID: 30902997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipophilic recombinant-protein insertion endows lymphocytes with enhanced targeting-infiltration ability in EGFR positive cancer.
    Du S; Sha H; Ding N; Yang J; Qian H; Zhou S; Su S; Meng F; Chen H; Chen F; Zhang L; Liu B; Wei J
    Cell Immunol; 2021 Jul; 365():104376. PubMed ID: 33984534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Penetrating Peptide-Functionalized Tenascin-C Antibody for Glioblastoma Targeting.
    Lingasamy P; Laarmann AH; Teesalu T
    Curr Cancer Drug Targets; 2021; 21(1):70-79. PubMed ID: 33001014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of IL-24 by tumor penetrating peptide iRGD enhanced its antitumor efficacy against non-small cell lung cancer.
    Yang J; Yang J; Wei Y; Yin H; Fang L; Chai D; Li H; Li H; Zhang Q; Zheng J
    Int Immunopharmacol; 2019 May; 70():125-134. PubMed ID: 30798161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC.
    Zhang Y; Yang J; Ding M; Li L; Lu Z; Zhang Q; Zheng J
    Oncol Lett; 2016 Nov; 12(5):3241-3249. PubMed ID: 27899989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation.
    Hu C; Huang Y; Chen Y
    Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery.
    Kang S; Lee S; Park S
    Polymers (Basel); 2020 Aug; 12(9):. PubMed ID: 32847045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.
    Sugahara KN; Scodeller P; Braun GB; de Mendoza TH; Yamazaki CM; Kluger MD; Kitayama J; Alvarez E; Howell SB; Teesalu T; Ruoslahti E; Lowy AM
    J Control Release; 2015 Aug; 212():59-69. PubMed ID: 26071630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-Penetrating Peptide Enhances Antitumor Effects of IL-24 Against Prostate Cancer.
    Yang J; Yin H; Yang J; Wei Y; Fang L; Chai D; Zhang Q; Zheng J
    Transl Oncol; 2019 Mar; 12(3):453-461. PubMed ID: 30580153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
    Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
    Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose radiotherapy synergizes with iRGD-antiCD3-modified T cells by facilitating T cell infiltration.
    Zhou S; Zhu M; Wei X; Mu P; Shen L; Wang Y; Wan J; Zhang H; Xia F; Zhang Z
    Radiother Oncol; 2024 May; 194():110213. PubMed ID: 38458258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Strategy through Combining iRGD Peptide with Tumor-Microenvironment-Responsive and Multistage Nanoparticles for Deep Tumor Penetration.
    Cun X; Chen J; Ruan S; Zhang L; Wan J; He Q; Gao H
    ACS Appl Mater Interfaces; 2015 Dec; 7(49):27458-66. PubMed ID: 26633260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Therapy with iRGD-antiCD3 and PD-1 Blockade Enhances Antitumor Potency of Cord Blood-Derived T Cells.
    Zhu M; Wang H; Zhou S; Wei J; Ding N; Shao J; Yu L; Feng Z; Liu B
    Onco Targets Ther; 2021; 14():835-844. PubMed ID: 33574677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining iRGD with HuFOLactis enhances antitumor potency by facilitating immune cell infiltration and activation.
    Shao J; Xin K; Qian Z; Liu F; Li L; Zhu J; Liu Q; Tian M; Liu B
    Hum Vaccin Immunother; 2024 Dec; 20(1):2375825. PubMed ID: 39101772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer therapy with iRGD as a tumor-penetrating peptide.
    Thirumalai A; Girigoswami K; Pallavi P; Harini K; Gowtham P; Girigoswami A
    Bull Cancer; 2023 Dec; 110(12):1288-1300. PubMed ID: 37813754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing Accumulation and Penetration of HPMA Copolymer-Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer.
    Peng ZH; Kopeček J
    J Am Chem Soc; 2015 Jun; 137(21):6726-9. PubMed ID: 25963409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.